Bevacizumab, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer

DISEASE CHARACTERISTICS:

Histologically confirmed adenocarcinoma of the prostate

High-risk, locally advanced disease (T2b-T4 disease), meeting 1 of the following criteria:

Gleason score 8-10

Prostate-specific antigen > 20 ng/dL AND Gleason score 7

T2a disease allowed provided ≥ 5 biopsies contain Gleason score 4 +3 cancer (minimum of 10 biopsies total required)
No evidence of metastatic disease within the past 60 days by physical examination, chest x-ray, bone scan, and CT scan of abdomen and pelvis

PATIENT CHARACTERISTICS:

ECOG performance status 0-2
Hemoglobin > 8 g/dL
Absolute granulocyte count ≥ 1,500/mm³
Platelet count ≥ 100,000/mm³
Bilirubin ≤ 1.5 times upper limit of normal (ULN)
Creatinine ≤ 1.5 times ULN
Blood pressure ≤ 150/100 mm Hg

No cardiovascular disease, including any of the following:

Unstable angina
New York Heart Association class II-IV congestive heart failure
History of myocardial infarction within the past 6 months
History of stroke within the past 6 months

PRIOR CONCURRENT THERAPY:

At least 4 weeks since prior major surgery
No prior hormonal therapy (except finasteride for obstructive voiding symptoms) for prostate cancer
No prior or concurrent chemotherapy, biologic therapy, or radiotherapy for prostate cancer